Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP8 | P40818 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170131 | 0.78 | NOS3 (0.46) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL12498325 | 0.78 | EGLN2 (0.36) | TDO2EGLN2GAAKDM4EALDH1A1 | |
| SCHEMBL14830700 | 0.78 | MAP4K1 (0.48) | TDO2 | |
| SCHEMBL15691383 | 0.77 | ALDH1A1 (0.39) | CCR1CCR5CCR8NOS3NOS2 | |
| SCHEMBL29672973 | 0.75 | KDM4E (0.40) | TDO2EGLN2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14842294 | 0.75 | TDO2 (0.33) | TDO2EGLN2IDO1ERBB2 | |
| SCHEMBL17868286 | 0.75 | TDO2 (0.39) | TDO2EGLN2ALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL3095407 | 0.75 | KDM4E (0.40) | TDO2EGLN2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2596919 | 0.75 | TDO2 (0.36) | TDO2EGLN2IDO1ERBB2 | |
| SCHEMBL23500465 | 0.75 | ALDH1A1 (0.36) | CCR1CCR5CCR8NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109918-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022106469-A2 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| CN-110156772-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| EP-3089746-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2016-11-09 | — | — | EP | disclosed |
| EP-2121638-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2222661-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| US-8404856-B2 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| CN-101952274-A | Non-nucleoside reverse transcriptase inhibitor | MERCK & CO INC | 2011-01-19 | — | — | CN | disclosed |
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME LLC | 2008-11-06 | — | — | US | disclosed |
| WO-2008076225-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007019130-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019098-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019101-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019100-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1189899-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6455532-B1 | ANTICOAGULANTS | MERCK & CO., INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1189899-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000075134-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | RNGTT, RRM2B, RRM2 | CCR1 646/4885CCR5 877/4885CCR8 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.